Who Paid My Doc
Arzerra
Drug Hematology
NDC 0078-0669-13
General payments
$195,052
Research payments
$128,432,537
Through program year 2025, $195,052 in general payments and $128,432,537 in research payments were reported against Arzerra (Hematology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
12 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $3,066 | 5 |
| 2025 | Research | $2,474,255 | 37 |
| 2023 | General | $16,696 | 7 |
| 2023 | Research | $373,965 | 11 |
| 2022 | General | $91,882 | 29 |
| 2022 | Research | $58,543,981 | 409 |
| 2021 | General | $250 | 24 |
| 2021 | Research | $39,426,749 | 292 |
| 2020 | General | $1,590 | 135 |
| 2020 | Research | $19,044,704 | 238 |
| 2019 | General | $81,569 | 79 |
| 2019 | Research | $8,568,882 | 264 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
279 general · 1,251 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.